Sarah M. London Net Worth

The estimated Net Worth of Sarah London is at least $23.1 Million dollars as of 17 March 2023. Ms London owns over 30,000 units of Centene stock worth over $23,066,127 and over the last 4 years she sold CNC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms London CNC stock SEC Form 4 insiders trading

Ms has made over 1 trades of the Centene stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 30,000 units of CNC stock worth $1,878,000 on 17 March 2023.

The largest trade she's ever made was buying 30,000 units of Centene stock on 17 March 2023 worth over $1,878,000. On average, Ms trades about 1,429 units every 0 days since 2021. As of 17 March 2023 she still owns at least 313,953 units of Centene stock.

You can see the complete history of Ms London stock trades at the bottom of the page.

Ms. Sarah M. London biography

Sarah M. London is the Pres of Health Care Enterprises & Exec. VP of Advanced Technology & Vice Chairman at Centene.

How old is Ms London?

Ms London is 40, she's been the Pres of Health Care Enterprises & Exec. VP of Advanced Technology & Vice Chairman of Centene since . There are 29 older and 1 younger executives at Centene. The oldest executive at Centene Corp. is Robert Ditmore, 86, who is the Presiding Independent Director.

What's Ms London's mailing address?

Sarah's mailing address filed with the SEC is 7700, Forsyth Boulevard, Clayton, Saint Louis County, Missouri, 63105, United States.

Insiders trading at Centene

Over the last 21 years, insiders at Centene have traded over $221,714,329 worth of Centene stock and bought 119,005 units worth $6,904,837 . The most active insiders traders include Frederick H Eppinger, Michael F Neidorff, and Edward L Cahill. On average, Centene executives and independent directors trade stock every 18 days with the average trade being worth of $1,257,880. The most recent stock trade was executed by Christopher J Coughlin on 14 May 2024, trading 878 units of CNC stock currently worth $67,387.

What does Centene do?

centene corporation, a fortune 500 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. many receive benefits provided under medicaid, including the state children's health insurance program (chip), as well as aged, blind or disabled (abd), foster care and long term care (ltc), in addition to other state-sponsored/hybrid programs, and medicare (special needs plans). the company operates local health plans and offers a range of health insurance solutions. it also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, in-home health services, life and health management, managed vision, pharmacy benefits management, specialty pharmacy and telehealth services.

Complete history of Ms London stock trades at Centene

Centene executives and stock owners

Centene executives and other stock owners filed with the SEC include:

• Michael Neidorff,
  Chairman of the Board, President, Chief Executive Officer
• Jeffrey Schwaneke,
  Chief Financial Officer, Executive Vice President, Treasurer
• Brandy Burkhalter,
  Executive Vice President - Operations
• Michael Frederic Neidorff,
  Chairman & CEO
• Jesse Hunter,
  Executive Vice President and Chief Strategy Officer
• Mark Brooks,
  Executive Vice President, Chief Information Officer
• Jeffrey Alan Schwaneke CPA, CPA,
  Exec. VP, CFO & Treasurer
• Keith Williamson,
  Executive Vice President, General Counsel, Secretary
• Brandy Lynn Burkhalter,
  Exec. VP
• Mark J. Brooks,
  Exec. VP & Chief Information Officer
• Frederick Eppinger,
  Independent Director
• John Roberts,
  Independent Director
• Robert Ditmore,
  Presiding Independent Director
• David Steward,
  Independent Director
• Tommy Thompson,
  Independent Director
• Jessica Blume,
  Independent Director
• Orlando Ayala,
  Independent Director
• Lori Robinson,
  Independent Director
• Richard Gephardt,
  Independent Director
• William Trubeck,
  Independent Director
• H. James Dallas,
  Independent Director
• Jennifer Gilligan,
  Senior Vice President of Investor Relations
• Christopher Koster,
  Senior Vice President, General Counsel, Secretary
• Christopher Isaak,
  Senior Vice President, Corporate Controller and Chief Accounting Officer
• Jonathan Dinesman,
  Executive Vice President - Government Relations
• Kenneth Burdick,
  Executive Vice President - Markets & Products
• H. Robert Sanders,
  Executive Vice President of Human Resources
• Shannon Bagley,
  Executive Vice President of Human Resources
• David Thomas,
  Executive Vice President - Marketing
• Katie Nicole Casso,
  Sr. VP, Chief Accounting Office & Corp. Controller
• Christopher Andrew Koster,
  Sr. VP, Gen. Counsel & Sec.
• Katie Casso,
  Sr. VP, Chief Accounting Office & Corp. Controller
• Andrew Lynn Asher,
  Exec. VP & CFO
• Brent Davis Layton,
  Pres & COO
• Sarah M. London,
  Pres of Health Care Enterprises & Exec. VP of Advanced Technology & Vice Chairman
• Patrick John Rooney,
  Sr. VP of Health Plans
• Matthew Snyder,
  Sr. VP of Internal Audit, Compliance & Risk Management
• Christopher Russell Isaak B.B.A., CPA,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• Monte E Ford,
  Director
• Cynthia J Brinkley,
  EVP, International Operations
• Christopher D Bowers,
  EVP, Markets
• Carol Goldman,
  Sr VP Chief Admin Officer
• Kenneth Rone Baldwin,
  EVP, Insurance Group
• James E Murray,
  EVP, Chief Operating Officer
• Donald G Imholz,
  SVP, Chief Information Officer
• William Scheffel,
  Senior VP and Controller
• Pamela A Joseph,
  Director
• Vicki B Escarra,
  Director
• Leslie V Norwalk,
  Director
• Christopher J Coughlin,
  Director
• Theodore R. Ii Samuels,
  Director
• Wayne S De Veydt,
  Director
• Catherine M Halverson,
  Senior VP Business Development
• Edmund E Kroll,
  SVP Fin & Investor Relations
• Brian G Spanel,
  Senior Vice President and CIO
• Karen Bedell,
  SVP New Bus Integ & Develop
• Robert T Hitchcock,
  EVP Health Plans
• Cary Hobbs,
  Sr VP Strategy and Imp.
• Marie J Glancy,
  VP Government Relations
• Jason M Harrold,
  SVP, Specialty Business Unit
• Karey L Witty,
  Senior Vice President and CFO
• J Per Brodin,
  Senior Vice President and CFO
• Eric Slusser,
  Executive VP & CFO
• Patti Darnley,
  Sr. VP of Operations
• Lisa M Wilson,
  VP Investor Relations
• Mark W Eggert,
  Executive VP, Health Plans
• Mary V Mason,
  SVP & Chief Medical Officer
• Edward L Cahill,
  Director
• Frederick J Manning,
  Executive Vice President
• Richard P Wiederhold,
  Director
• James D Jr Donovan,
  Senior VP Product Development
• Steve Bartlett,
  Director
• C David Minifie,
  EVP, Chief Marketing Officer
• Glendon A Schuster,
  Senior VP and CIO
• Samuel E Bradt,
  Director
• Antonette Simonetti,
  SVP, Public Affairs
• Joseph P Jr Drozda,
  Executive VP Operations
• John Tadich,
  Senior VP, Specialty Companies
• Claire W Johnson,
  Director
• Dan Paquin,
  Sr. VP New Plan Implementation
• Andrew Lynn Asher,
  Chief Financial Officer
• Susan Raye Smith,
  Chief Operating Officer
• Brent D Layton,
  President & COO
• Sarah London,
  Chief Executive Officer
• Colin A Toney,
  EVP, Mergers & Acquisitions
• Katie Casso,
  Corporate Controller & CAO
• Kenneth J Fasola,
  President